The European Medicine Agency’s Committee for Medicinal Products for Human Use recommended the approval of Opdivo plus platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer at a high risk of recurrence in adult patients with tumor cell PD-L1 expression ≥1%.
Research from the University of Pittsburgh explains why metastatic uveal melanoma is resistant to conventional immunotherapies and how adoptive therapy, which involves growing a patient’s T cells outside the body before reinfusing them, can successfully treat this rare and aggressive cancer.
